XM Therapeutics
Frank Ahmann is an accomplished leader in the biomedical industry with extensive experience in various executive roles. Currently serving as Chief Business Officer at TriFlo Cardiovascular Inc. and CoFounder, President & CEO at XM Therapeutics, Frank has a strong background in developing innovative medical technologies. Previous positions include Chief Operating Officer at Recardio, Inc., where Frank contributed to the development of a small molecule for Acute Myocardial Infarction, and CoFounder & Chief Executive Officer at MateraCor, where Frank's leadership led to the company's acquisition by Bioventrix, Inc. Additionally, Frank held pivotal roles at LoneStar Heart, Inc. as President & CEO, focusing on new therapies for advanced heart failure, and has a history of enhancing operational strategies at companies such as CardioPolymers, Inc. and Allvivo, Inc. Educational credentials include an MBA from Columbia Business School and a BBA from the Texas McCombs School of Business.
This person is not in any teams
This person is not in any offices
XM Therapeutics
The Extracellular Matrix (ECM) - the scaffolding material that organizes cells into tissues and organs - is a proactive participant in chronic disorders enabling continued inflammation, fibrosis and ischemia. Spun off from Brown University in 2022, XM Therapeutics is developing a platform technology to directly modulate the dysfunctional ECM to improve tissue function and enable organ repair. We generate injectable, acellular designer ECM Particles sourced from human 3D cell cultures. Our initial focus is on cardiovascular and pulmonary indications with significant additional potential in other diseases. We are a Providence, RI - based seed stage start-up with a clear mission: to improve the health status of patients with chronic disorders by modulating and repairing the dysfunctional Extracellular Matrix.